Effects of acute doxorubicin treatment on hepatic proteome lysine acetylation status and the apoptotic environment. World J Biol Chem 2014 Aug 26;5(3):377-86 PMID: 25225604 PMCID: PMC4160530
Abstract
AIM: To determine if doxorubicin (Dox) alters hepatic proteome acetylation status and if acetylation status was associated with an apoptotic environment.
METHODS: Doxorubicin (20 mg/kg; Sigma, Saint Louis, MO; n = 8) or NaCl (0.9%; n = 7) was administered as an intraperitoneal injection to male F344 rats, 6-wk of age. Once animals were treated with Dox or saline, all animals were fasted until sacrifice 24 h later.
RESULTS: Dox treatment decreased proteome lysine acetylation likely due to a decrease in histone acetyltransferase activity. Proteome deacetylation may likely not be associated with a proapoptotic environment. Dox did not increase caspase-9, -8, or -3 activation nor poly (adenosine diphosphate-ribose) polymerase-1 cleavage. Dox did stimulate caspase-12 activation, however, it likely did not play a role in apoptosis induction.
CONCLUSION: Early effects of Dox involve hepatic proteome lysine deacetylation and caspase-12 activation under these experimental conditions.
Author List
Dirks-Naylor AJ, Kouzi SA, Bero JD, Tran NT, Yang S, Mabolo RAuthor
Sendra Yang PharmD Assistant Clinical Professor in the School of Pharmacy department at Medical College of WisconsinView this publication's entry at the Pubmed website PMID: 25225604
